RecruitingNot Applicable

Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces

China500 participantsStarted 2025-06-01

Plain-language summary

The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are: * What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;
✓. Patients who have undergone surgical lung resection;
✓. Patients with complete preoperative chest CT imaging data;
✓. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.

Exclusion criteria

✕. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \[LAM\], or Birt-Hogg-Dubé \[BHD\] syndrome);
✕. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
✕. Patients with concurrent other malignancies;
✕. Patients with missing or poor-quality preoperative chest CT imaging data.

What they're measuring

DFS

Timeframe: From enrollment to the end of surgery for 5 years

Trial details

NCT IDNCT07066813

SponsorCentral South University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-31

Contact for this trial

Chen Chen

+8673185295188 chenchen1981412@csu.edu.cn

View on ClinicalTrials.gov More Lung Cancer Associated With Cystic Airspaces trials